湖南裕能(301358.SZ):產品銷量大幅增長,預計一季度出貨量超20萬噸
格隆匯3月18日丨湖南裕能(301358.SZ)於近期投資者關係活動表示,2024年,公司磷酸鹽正極材料銷量創下公司歷史新高,其中,應用在儲能領域的產品銷量佔比已提升至約41%。新產品方面,CN-5系列、YN-9系列和YN-13系列在2024年下半年合計銷售約11.13萬噸,在2024年下半年的總銷量比例約27%。今年以來,行業依舊維持較高的景氣度,與去年同期相比,公司產品銷量大幅增長,預計一季度出貨量超20萬噸。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.